Low-level laser therapy, often called LLLT or photobiomodulation, is an FDA-cleared treatment for hair loss that operates on a completely different mechanism than any drug. It uses specific wavelengths of light to stimulate follicle activity, and the clinical evidence supporting it has grown substantially over the past decade. This article explains how low-level laser therapy works, what the clinical trials show, what devices are available, and how it fits into a comprehensive hair loss protocol.
What Is Low-Level Laser Therapy?
Low-level laser therapy uses red and near-infrared light, usually in the 630 to 670 nanometer range, at low power levels. Unlike surgical lasers, which cut or ablate tissue through heat, low-level laser therapy operates at power levels too low to produce heat damage. Instead, cells absorb the light energy and respond biologically.
The FDA has cleared multiple low-level laser therapy devices for hair loss treatment, including handheld laser combs, laser caps, and laser bands. This clearance is based on demonstrated safety and efficacy in clinical trials, though it is not the same level of evidence as drug approval.
Low-level laser therapy is not a medication treatment. It is a physical treatment that uses light energy to stimulate follicle biology. FDA-cleared devices have clinical trial data supporting their use.
The Proposed Mechanisms
The main cellular target for low-level laser therapy appears to be cytochrome c oxidase, an enzyme involved in cellular energy production. When photons in the red and near-infrared range are absorbed by cytochrome c oxidase, they increase mitochondrial activity and ATP production. More ATP means more cellular energy available for growth and repair.
In hair follicles, this increased mitochondrial activity is believed to:
- Extend the anagen (growth) phase of the hair cycle
- Promote the shift from telogen (resting) to anagen
- Improve blood flow to the follicle through nitric oxide release
- Reduce oxidative stress and inflammation in the follicle environment
These mechanisms are consistent with low-level laser therapy's effects in other tissue types, where photobiomodulation has well-documented effects on wound healing, inflammation, and cellular proliferation.
Low-level laser therapy works through cellular energy production, not hormonal pathways. It does not affect DHT and works through a mechanism entirely separate from finasteride, dutasteride, or minoxidil.
Clinical Evidence: What the Trials Show
A 2014 randomized double-blind controlled trial studied the use of a 655 nm laser comb device or a sham device three times per week for 26 weeks. Terminal hair density increased by 51% in the treatment group versus 22% in the sham group — a statistically significant difference.
A 2013 multicenter randomized controlled trial found that hair counts increased meaningfully in the laser group compared to sham.
Looking at the research as a whole, a 2018 systematic review and meta-analysis examined 11 randomized controlled trials totaling 680 participants. It found that low-level laser therapy significantly improved hair density and hair count compared to sham treatment. These results were true for both men and women with androgenetic alopecia.
Multiple randomized controlled trials and a meta-analysis confirm that low-level laser therapy increases hair density meaningfully compared to sham treatment. The effect is real and reproducible.
Comparing LLLT to Drug Treatments
Low-level laser therapy is generally considered less potent than finasteride or minoxidil as a standalone treatment. It does not suppress DHT, meaning the hormonal driver of androgenetic alopecia remains active. Its effects are primarily on optimizing the follicle environment and extending the growth phase, not on addressing the underlying cause.
Where low-level laser therapy shines is in its mechanism being entirely complementary to both medication treatments. A patient on finasteride and minoxidil who adds low-level laser therapy is adding a third pathway — photobiomodulation — that does not overlap with either drug's mechanism.
A 2020 study found that the combination of minoxidil and low-level laser therapy produced meaningfully greater improvement in hair density than minoxidil alone in men with androgenetic alopecia. The additive effect supports using low-level laser therapy as a complement rather than an alternative.
Low-level laser therapy is less effective than finasteride or minoxidil as a standalone treatment for androgenetic alopecia. As an add-on, it adds a genuinely different mechanism that appears to compound with drug treatments.
Device Types and Usage
Multiple FDA-cleared devices are available in different form factors:
Laser caps: Worn on the head like a cap, delivering multiple laser diodes to the entire scalp simultaneously. Typical protocols are 20–30 minutes every other day.
Laser combs: Handheld devices that the user moves across the scalp. Require more active involvement and technique for consistent coverage.
Diode counts in commercial devices range from a few dozen to over 200. Higher diode counts can deliver more energy in the same treatment time but are not the only relevant variable. Wavelength, power density, and treatment protocol also matter.
The standard treatment frequency in most clinical trials is three times per week, with sessions of 20–25 minutes. Consistent use over 6 to 12 months is required to see results.
Laser caps provide more consistent scalp coverage than laser combs and are generally preferred for consistency. Any FDA-cleared device used according to protocol is clinically supported. Safety Profile
Low-level laser therapy has an excellent safety profile. No serious adverse events have been reported in clinical trials. Some users report mild scalp warmth or tingling during use, which is generally transient.
Contraindications include scalp conditions such as active psoriasis or eczema in the treatment area, photosensitivity disorders, and use of photosensitizing medications. Patients with these factors should consult a clinician before starting.
Low-level laser therapy is one of the safest treatments available for hair loss. The absence of systemic effects makes it appropriate for patients who cannot take or prefer to avoid medication treatments. Summary
Low-level laser therapy is an FDA-cleared treatment for androgenetic alopecia with a growing body of randomized controlled trial evidence. It works through photobiomodulation — stimulating mitochondrial activity, extending the anagen phase, and reducing follicle inflammation — through a mechanism separate from finasteride and minoxidil. As a standalone treatment it is less potent than medication options. As an add-on, it adds a genuinely different pathway and has demonstrated additive benefit in combination with minoxidil. Consistent use over 6 to 12 months is required, and the safety profile is excellent.